Related Experiment Video
Updated: Dec 31, 2025
07:32
Assessing Iron Deposition in the Brains of 5xFAD Mice by Perls'/DAB Staining
Published on: May 23, 2025
973
Liposomal iron in moderate chronic kidney disease
Enrique Montagud-Marrahi1, Pilar Arrizabalaga1, Rosa Abellana2
1Servicio de Nefrología y Trasplante Renal, Instituto Clínico de Nefrología y Urología, Hospital Clínic de Barcelona, Barcelona, España.
Nefrologia
|January 2, 2020
Summary
Liposomal iron (FeSu) effectively raises hemoglobin in patients with stage 3 chronic kidney disease (CKD) who experience gastrointestinal issues with standard oral iron. This treatment shows high adherence and tolerability over 12 months.
Area of Science:
- Nephrology
- Hematology
- Pharmacology
Background:
- Debate exists on optimal iron supplementation route (oral vs. IV) for non-dialysis chronic kidney disease (CKD) patients.
- A novel oral liposomal iron (FeSu) offers high bioavailability and reduced side effects.
- Gastrointestinal intolerance limits conventional oral iron therapy in CKD patients.
Purpose of the Study:
- To evaluate the efficacy of liposomal iron (FeSu) in patients with stage 3 CKD.
- To assess FeSu in patients intolerant to traditional oral iron preparations.
- To determine hemoglobin increase, adherence, and adverse effects of FeSu over 12 months.
Main Methods:
- Prospective observational study.
- 37 patients with stage 3 CKD and GI intolerance to oral iron received 30mg/day FeSu for 12 months.
- Primary outcome: hemoglobin increase at 6 and 12 months; secondary outcomes: adherence and adverse effects.
Main Results:
- Hemoglobin increased significantly at 6 and 12 months (0.49±0.19 and 0.36±0.19 g/dL, P<.05) versus baseline.
- Despite eGFR decline, FeSu demonstrated 100% adherence.
- No adverse events required treatment suspension, indicating excellent tolerability.
Conclusions:
- Liposomal iron (FeSu) is an effective treatment for anemia in stage 3 CKD patients with GI intolerance.
- FeSu offers a well-tolerated oral alternative to conventional iron therapies.
- The study supports FeSu's role in managing anemia in moderate CKD populations.
Related Concept Videos
01:28Chronic Kidney Disease III: Interprofessional Care
293
Chronic kidney disease (CKD) requires collaborative and comprehensive management. CKD progresses through stages and can lead to end-stage kidney disease (ESKD) if untreated. Interprofessional collaboration and patient education are crucial, enabling patients to manage their health and improve their quality of life.Diagnostic approach for chronic kidney diseaseThe diagnosis of CKD primarily focuses on the glomerular filtration rate (GFR), which assesses kidney function by measuring how well...
293
01:11Renal Failure: Dose Adjustments
375
In patients with renal impairment, drugs undergo significant changes in their pharmacokinetics, which require dosage adjustments to ensure safe and effective therapy.
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
375
01:24Chronic Kidney Disease II: Clinical Manifestations
486
Chronic Kidney Disease (CKD) progressively impairs multiple body systems due to the accumulation of uremic toxins, which disrupt cellular functions across various organs.Neurologic symptomsNeurologic symptoms often arise early in CKD, as uremic toxin buildup drives changes in cognitive and motor functions. Patients frequently experience fatigue, headache, confusion, difficulty concentrating, and, in severe cases, seizures. Peripheral neuropathy commonly manifests as burning sensations in the...
486
01:25Chronic Kidney Disease I: Introduction
505
Chronic Kidney Disease (CKD) arises when the kidneys progressively lose their ability to function, ultimately leading to end-stage renal disease. At this advanced stage, the kidneys can no longer filter waste or maintain essential body functions, requiring renal replacement therapy (RRT) through dialysis or a kidney transplant for survival.Early-stage chronic kidney disease and detection challengesIn CKD's early stages, symptoms often remain absent because healthy nephrons compensate for...
505
01:18Chronic Kidney Disease IV: Nursing Management
252
Nursing management is essential for preventing complications, maintaining stability, and improving patients' quality of life in chronic kidney disease (CKD). By using a structured approach, nurses help slow CKD progression and support effective patient care.1. Comprehensive patient assessmentEffective management begins with nurses reviewing the patient’s medical history, and identifying key risk factors like diabetes, hypertension, and nephrotoxic drug use. Nurses assess signs of...
252
01:25Drug Dosing in Renal Diseases: Dose Adjustments Based on Drug Clearance and Elimination Rate Constant
166
In patients with renal disease, dosage adjustments are necessary to maintain therapeutic plasma drug concentrations and prevent toxicity or subtherapeutic exposure. Renal impairment alters drug pharmacokinetics, especially in conditions like uremia, where changes such as prolonged elimination half-life and altered apparent volume of distribution can significantly affect drug disposition. These changes require careful modification of the dosing regimen to achieve the desired clinical...
166